1. Scrip
  2. >>Therapy Areas

BI's Praxbind US Approval May Boost Pradaxa Sales

 
• By Donna Young

The FDA on Oct. 16 gave privately held Boehringer Ingelheim GmgH the go-ahead to market its humanized monoclonal antibody fragment Praxbind (idarucizumab) under an accelerated approval as an agent to reverse the blood-thinning effects of the company's highly popular anticoagulant Pradaxa (dabigatran) in emergency surgery or urgent procedures or in situations when there's life-threatening or uncontrolled bleeding.

The FDA on Oct. 16 gave privately held Boehringer Ingelheim GmgH the go-ahead to market its humanized monoclonal antibody fragment Praxbind (idarucizumab) under an accelerated approval as an agent to reverse the blood-thinning effects of the company's highly popular anticoagulant Pradaxa (dabigatran) in emergency surgery or urgent procedures or in situations when there's life-threatening or uncontrolled bleeding.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.